Why Most Medication Reduction Attempts Fail
The pattern is familiar to many patients who have tried to reduce their HS medications: symptoms worsen within days to weeks of reducing the dose, the reduction is reversed, and the conclusion drawn is that the medication is necessary and cannot be stopped. This conclusion is usually incorrect — but the failure that leads to it is genuine. Understanding why it happens requires understanding what suppressive medications are actually doing in the HS system.
Long-term suppressive medications in HS — antibiotics, corticosteroids, biologics — work by reducing the activity of the inflammatory system that is driving HS. They do not correct the internal drivers of that inflammation: gut dysfunction, hormonal imbalance, immune dysregulation, metabolic disruption. While the medication is active, it is providing external management of a system that has not been internally corrected. The disease is being controlled rather than corrected, and the controlling agent is the medication.
When the medication is reduced without internal correction having occurred, the inflammatory system that the medication was managing returns to the activity level it would have had without the medication — which is the level determined by the uncorrected internal drivers. In many cases, this return happens faster than the slow pace at which symptoms developed originally, because the suppressed inflammatory system has maintained its underlying drive throughout the period of suppression. The result is rebound: symptoms return, often acutely, and the reduction is interpreted as a failure rather than as a correct observation that internal correction was not yet sufficient to replace the medication's controlling function.
"If it keeps coming back, it means the root cause has not been addressed."
The Prerequisite: Internal Correction First
The central principle of successful medication reduction in HS is that internal correction must precede or at minimum accompany reduction — not follow it. Reduction attempted before sufficient internal correction has been achieved will produce rebound. Reduction attempted after internal correction has been substantially consolidated is a different clinical situation: the internal environment has been changed to one that is less dependent on external inflammatory suppression, and the medication is managing a smaller inflammatory load that the corrected system is increasingly capable of managing without external support.
What constitutes sufficient internal correction to begin considering medication reduction is a clinical judgement that depends on the individual patient's profile. There are, however, observable markers that indicate the internal environment has shifted meaningfully: sustained reduction in systemic inflammatory symptoms between medication doses (reduced fatigue, better sleep quality, improved gut function); reduction in flare frequency that precedes any change in medication; improvement in hormonal markers where hormonal involvement was a primary driver; and a subjective sense of internal stability that is qualitatively different from the stability that the medication alone was providing.
These markers do not indicate that the medication can be stopped. They indicate that the internal environment has changed sufficiently that reduction can be attempted in a staged way, with monitoring, and with a plan for managing any rebound that indicates the reduction has moved faster than the internal correction can support.
The Staging Principle
Medication reduction in HS is not a binary transition from full dose to none. It is a staged process in which each reduction step is held for long enough to assess whether the internal correction that has been achieved is sufficient to sustain that level of reduced medication load. Each stage is a test of the internal system's self-regulatory capacity at that level of external support withdrawal.
The pace of staging is determined by the response at each step, not by a pre-set schedule. If a reduction step produces minimal response — the inflammatory system remains at a level that the internal correction can manage — the reduction can continue to the next stage after a consolidation period. If a reduction step produces significant rebound, it indicates that the internal correction at that stage is not yet sufficient to replace the withdrawn level of external support, and the step should be partially reversed while internal correction is continued and consolidated further before attempting reduction again.
This is not failure — it is clinical information. Rebound at a particular reduction step identifies the level at which internal correction is currently operating, and indicates what degree of further correction is needed before the next stage can be attempted successfully. Treating rebound as information rather than as evidence that medication cannot be reduced changes how both patient and clinician interpret it.
In Ayurvedic clinical practice, the transition from active therapeutic intervention to maintenance and then to independence from intervention is understood as a gradual withdrawal of external support as internal strength — Bala — is rebuilt. The texts describe this as Krama — a sequential, stepwise process in which each stage is consolidated before the next is attempted. Applied to medication reduction in HS, this means building the Agni (metabolic and digestive strength), restoring Dhatu integrity, and rebuilding Ojas (fundamental vitality and regulatory capacity) to the point where the system can self-regulate at each progressively lower level of external support. Attempting to accelerate this sequence produces the clinical equivalent of withdrawing a walking support before the patient has sufficient strength to stand independently — the result is a fall that is then incorrectly attributed to the patient's inability to walk rather than to the premature withdrawal of support.
Medication-Specific Considerations
Different suppressive medications used in HS require different reduction approaches based on their mechanisms and the specific dependencies they create.
Long-Term Antibiotics
Long-term antibiotic use in HS creates a specific dependency: the gut microbiome has been maintained in a state shaped by continuous antibiotic exposure. Reduction of antibiotic use, if undertaken while gut health is being actively restored, needs to account for the transitional period in which the microbiome is shifting from antibiotic-shaped to restoration-shaped. This transition can temporarily increase gut permeability and systemic inflammatory signalling, which may manifest as a brief increase in HS activity before the restored microbiome begins producing its own anti-inflammatory effects.
Gradual reduction — decreasing dose or frequency rather than abrupt cessation — gives the gut microbiome restoration process time to consolidate at each step before the next reduction is attempted. The pace of antibiotic reduction should be calibrated against observable gut health markers: improved digestive function, reduced bloating and gut discomfort, and more stable systemic energy levels between antibiotic doses all indicate that the microbiome is consolidating sufficiently to support further reduction.
Corticosteroids
Corticosteroid reduction in HS — whether from systemic use or frequent intralesional injections — requires particular care because corticosteroids affect multiple regulatory systems simultaneously: immune function, adrenal function, metabolic regulation, and connective tissue integrity. Prolonged corticosteroid use suppresses the body's own cortisol production, and reduction must allow time for adrenal recovery alongside the HS-specific internal correction.
Very gradual reduction — typically slower than the patient's initial inclination — with monitoring of both HS symptoms and systemic signs of adrenal adjustment (fatigue, energy fluctuation, mood changes) is standard. Internal correction during this period specifically targets the inflammatory and metabolic drivers that corticosteroids were managing, reducing the load that the immune system must manage as external steroid support is withdrawn.
Biologics
Biologic medication reduction presents the most complex transition challenge. Biologics achieve their effect by precisely targeting specific inflammatory mediators, and the immune system adapts to their presence over time. When biologic treatment is reduced or discontinued, the immune system — which has been operating in a biologic-modified state — must readjust to operating without that specific mediator suppression.
The readjustment period can produce temporary rebound that is disproportionate to what the patient's internal correction would suggest, because the immune system's regulatory recalibration takes time. Internal correction specifically focused on rebuilding the regulatory immune capacity that biologics were supplementing — rather than replacing — is the priority during biologic reduction. Monitoring should extend over a longer period per reduction step than for other medication types, as the regulatory recalibration that follows biologic reduction is slower than the symptom changes it produces.
"The goal is not just to control symptoms, but to understand why the condition is occurring in the first place."
What Success in Medication Reduction Actually Looks Like
Successful medication reduction in HS does not look like a smooth, linear decrease from full dose to zero with unchanged symptoms throughout. It looks like a staged process with occasional step-backs, periods of consolidation, and gradual extension of the intervals between medication doses or reductions in dose, against a background of progressively improving internal markers that indicate the system is increasingly capable of self-regulation.
A patient who has successfully reduced from daily antibiotics to intermittent use — required only during specific triggers or periods of increased stress — has achieved a qualitatively different relationship with medication than one who remains on continuous daily dosing. The medication is no longer maintaining a controlled state in an uncorrected system; it is providing targeted support during periods of elevated demand in a system that is managing its own baseline without it. This is a meaningful intermediate success even if the long-term goal is complete independence.
Complete medication independence — in the sense of maintaining HS stability without any suppressive medication — is achievable for patients whose internal correction reaches sufficient depth. It is not a starting point; it is an endpoint that is reached through staged reduction over a period that reflects how much internal correction was required in that patient's case. Setting this as the immediate target of medication reduction, rather than as the culmination of a structured process, produces the rebound and failure that makes patients conclude it cannot be done.